{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T04:51:02Z","timestamp":1766811062263,"version":"3.48.0"},"reference-count":19,"publisher":"Keio Journal of Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Keio J. Med.","Keio j. med"],"published-print":{"date-parts":[[2025]]},"DOI":"10.2302\/kjm.2025-0003-oa","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T18:07:26Z","timestamp":1751047646000},"page":"214-220","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of the Stability of 0.04% Mitomycin C Ophthalmic Solution          under Various Storage Conditions"],"prefix":"10.2302","volume":"74","author":[{"given":"Yuma","family":"Nonomiya","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for              Cancer Research, Tokyo, Japan"},{"name":"Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and              Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koki","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and              Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Yokoyama","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and              Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isana","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Cancer Institute Hospital, Japanese              Foundation for Cancer Research, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryusei","family":"Hara","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and              Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daigo","family":"Shoji","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and              Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Takiguchi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Cancer Institute Hospital, Japanese              Foundation for Cancer Research, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumi","family":"Takehana","sequence":"additional","affiliation":[{"name":"Clinical Laboratory Center, Cancer Institute Hospital, Japanese Foundation              for Cancer Research, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya","family":"Jibiki","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and              Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayo","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and              Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonori","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and              Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Tsuji","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Cancer Institute Hospital, Japanese              Foundation for Cancer Research, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for              Cancer Research, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1082","reference":[{"doi-asserted-by":"crossref","unstructured":"1. Hollhumer R, Williams S, Michelow P: Ocular          surface squamous neoplasia: population demographics, pathogenesis and risk factors. Afr          Vision Eye Health 2020; 79: a553. https:\/\/doi.org\/10.4102\/aveh.v79i1.553","key":"1","DOI":"10.4102\/aveh.v79i1.553"},{"doi-asserted-by":"crossref","unstructured":"2. Abraham LM, Selva D, Casson R, Leibovitch I:          Mitomycin. Drugs 2006; 66: 321\u2013340. PMID:16526821          https:\/\/doi.org\/10.2165\/00003495-200666030-00005","key":"2","DOI":"10.2165\/00003495-200666030-00005"},{"doi-asserted-by":"crossref","unstructured":"3. McKelvie PA, Daniell M: Impression cytology          following mitomycin C therapy for ocular surface squamous neoplasia. Br J Ophthalmol 2001;          85: 1115\u20131119. PMID:11520767 https:\/\/doi.org\/10.1136\/bjo.85.9.1115","key":"3","DOI":"10.1136\/bjo.85.9.1115"},{"doi-asserted-by":"crossref","unstructured":"4. Kusumesh R, Ambastha A, Kumar S, Sinha BP, Imam          N: Retrospective comparative study of topical interferon \u03b12b versus mitomycin C for          primary ocular surface squamous neoplasia. Cornea 2017; 36: 327\u2013331. PMID:28079688          https:\/\/doi.org\/10.1097\/ICO.0000000000001116","key":"4","DOI":"10.1097\/ICO.0000000000001116"},{"doi-asserted-by":"crossref","unstructured":"5. Hirst LW: Randomized controlled trial of topical          mitomycin C for ocular surface squamous neoplasia: early resolution. Ophthalmology 2007;          114: 976\u2013982. PMID:17241666 https:\/\/doi.org\/10.1016\/j.ophtha.2006.09.026","key":"5","DOI":"10.1016\/j.ophtha.2006.09.026"},{"unstructured":"6. US Department of Health and Human Services, Food          and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Center for          Veterinary Medicine (CVM): Bioanalytical method validation guidance for industry. 2018.          https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf          Accessed 15 April 2025.","key":"6"},{"unstructured":"7. European Medicine Agency: Bioanalytical method          validation. 2015. https:\/\/www.ema.europa.eu\/en\/bioanalytical-method-validation Accessed 15          April 2025.","key":"7"},{"doi-asserted-by":"crossref","unstructured":"8. Kawano K, Arai C, Anzai K, Nakajima S:          Pharmaceutical study of mitomycin C ophthalmic solutions. Jpn J Hospital Pharm 1993; 19:          230\u2013233. https:\/\/doi.org\/10.5649\/jjphcs1975.19.230","key":"8","DOI":"10.5649\/jjphcs1975.19.230"},{"doi-asserted-by":"crossref","unstructured":"9. Inaba K, Honda K, Otake H, Okamoto N, Shimomura          Y, Kotake T, Nagai N: Proposal of a new in vitro evaluation method using pH changes as an          indicator to evaluate irritation by ophthalmic solutions [in Japanese]. Iryo Yakugaku          2020; 46: 93\u201399. https:\/\/doi.org\/10.5649\/jjphcs.46.93","key":"9","DOI":"10.5649\/jjphcs.46.93"},{"doi-asserted-by":"crossref","unstructured":"10. Freiberg JC, Hedengran A, Heegaard S, Petrovski          G, Jacobsen J, Cvenkel B, Kolko M: An evaluation of the physicochemical properties of          preservative-free 0.005%(w\/v) latanoprost ophthalmic solutions, and the impact on in vitro          human conjunctival goblet cell survival. J Clin Med 2022; 11: 3137. PMID:35683527          https:\/\/doi.org\/10.3390\/jcm11113137","key":"10","DOI":"10.3390\/jcm11113137"},{"doi-asserted-by":"crossref","unstructured":"11. Garcia-Valldecabres M, L\u00f3pez-Alemany A, Refojo          MF: pH stability of ophthalmic solutions. Optometry 2004; 75: 161\u2013168. PMID:15058697          https:\/\/doi.org\/10.1016\/S1529-1839(04)70035-4","key":"11","DOI":"10.1016\/S1529-1839(04)70035-4"},{"doi-asserted-by":"crossref","unstructured":"12. Myers AL, Zhang YP, Kawedia JD, Zhou X,          Sobocinski SM, Metcalfe MJ, Kramer MA, Dinney CP, Kamat AM: Solubilization and stability          of mitomycin C solutions prepared for intravesical administration. Drugs R D 2017; 17:          297\u2013304. PMID:28470465 https:\/\/doi.org\/10.1007\/s40268-017-0183-y","key":"12","DOI":"10.1007\/s40268-017-0183-y"},{"doi-asserted-by":"crossref","unstructured":"13. Russell HC, Chadha V, Lockington D, Kemp EG:          Topical mitomycin C chemotherapy in the management of ocular surface neoplasia: a 10-year          review of treatment outcomes and complications. Br J Ophthalmol 2010; 94: 1316\u20131321.          PMID:20530655 https:\/\/doi.org\/10.1136\/bjo.2009.176099","key":"13","DOI":"10.1136\/bjo.2009.176099"},{"doi-asserted-by":"crossref","unstructured":"14. Takeda M, Yokoyama Y, Watanabe T, Hiraga Y,          Jibiki A, Kawazoe H, Suzuki S, Kadota K, Nakamura T: Evaluation of long-term storage          stability of antimicrobial agents, antiviral agents, and sodium chloride eye drops          prepared in the hospital [in Japanese]. Iryo Yakugaku 2021; 47: 316\u2013325.          https:\/\/doi.org\/10.5649\/jjphcs.47.316","key":"14","DOI":"10.5649\/jjphcs.47.316"},{"doi-asserted-by":"crossref","unstructured":"15. Fischer FH, Wiederholt M: Human precorneal tear          film pH measured by microelectrodes. Graefes Arch Clin Exp Ophthalmol 1982; 218: 168\u2013170.          PMID:7095445 https:\/\/doi.org\/10.1007\/BF02215658","key":"15","DOI":"10.1007\/BF02215658"},{"unstructured":"16. Gonnering R, Edelhauser HF, Van Horn DL, Durant          W: The pH tolerance of rabbit and human corneal endothelium. Invest Ophthalmol Vis Sci          1979; 18: 373\u2013390. PMID:34576","key":"16"},{"unstructured":"17. Hayakawa E, Sugiyama K, Furuya K, Kuroda T:          Stability of mitomycin C and adriamycin in frozen state [in Japanese]. Yukuzaigaku 1989;          49: 289\u2013296.","key":"17"},{"doi-asserted-by":"crossref","unstructured":"18. Al-Badriyeh D, Li J, Stewart K, Kong DC, Leung L,          Davies GE, Fullinfaw R, AI-Badriyeh D: Stability of extemporaneously prepared voriconazole          ophthalmic solution. Am J Health Syst Pharm 2009; 66: 1478\u20131483.          https:\/\/doi.org\/10.2146\/ajhp080110","key":"18","DOI":"10.2146\/ajhp080110"},{"doi-asserted-by":"crossref","unstructured":"19. Fuhrman LC, Jr, Stroman RT: Stability of          vancomycin in an extemporaneously compounded ophthalmic solution. Am J Health Syst Pharm          1998; 55: 1386\u20131388. PMID:9659967 https:\/\/doi.org\/10.1093\/ajhp\/55.13.1386","key":"19","DOI":"10.1093\/ajhp\/55.13.1386"}],"container-title":["The Keio Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/kjm\/74\/4\/74_2025-0003-OA\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T04:06:35Z","timestamp":1766808395000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/kjm\/74\/4\/74_2025-0003-OA\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2302\/kjm.2025-0003-oa","relation":{},"ISSN":["0022-9717","1880-1293"],"issn-type":[{"type":"print","value":"0022-9717"},{"type":"electronic","value":"1880-1293"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"2025-0003-OA"}}